General
Preferred name
Omaveloxolone
Synonyms
RTA-408 ()
RTA 408 ()
P&D ID
PD016358
CAS
1474034-05-3
Tags
available
drug
Approved by
FDA
First approval
2023
Drug Status
investigational
approved
Drug indication
Friedreich's ataxia
Psychiatric disorder
Melanoma
Max Phase
Phase 2
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Chemically RTA 408 is an analogue of , with difluoropropanamide replacing the carboxylic acid moiety.
This compound is covered by patent WO2013163344A1. The chemical structure represented above, was drawn from this patent.
This compound is covered by patent WO2013163344A1. The chemical structure represented above, was drawn from this patent.
DESCRIPTION
Chemically omaveloxolone (RTA 408) is a second generation synthetic oleanane triterpenoid compound, which structurally resembles , and has difluoropropanamide replacing the carboxylic acid moiety.
This compound is claimed in patent WO2013163344A1. The chemical structure represented above, was drawn from this patent, but structures with alternate stereochemistry are submitted in PubChem.
Pharmacologically omaveloxolone activates the Nrf2 transcription factor, to modulate expression of proteins that have antioxidative, anti-inflammatory, and mitochondrial bioenergetic activities . (GtoPdb)
This compound is claimed in patent WO2013163344A1. The chemical structure represented above, was drawn from this patent, but structures with alternate stereochemistry are submitted in PubChem.
Pharmacologically omaveloxolone activates the Nrf2 transcription factor, to modulate expression of proteins that have antioxidative, anti-inflammatory, and mitochondrial bioenergetic activities . (GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
2
Organisms
0
Compound Sets
14
Axon Medchem Screening Library
Cayman Chemical Bioactives
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
Guide to Pharmacology
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
16
Molecular Weight
554.33
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
2
Ring Count
5
Aromatic Ring Count
0
cLogP
6.73
TPSA
87.03
Fraction CSP3
0.76
Chiral centers
7.0
Largest ring
6.0
QED
0.41
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
NF-¦ÊB
Immunology/Inflammation
NF-??
Apoptosis
NF-κB
Target
Nrf2
NFE2L2
NRF2 acitivator
Keap1-Nrf2
STING
Member status
member
MOA
Erythroid Derived 2, Like 2 (Nrf2) Activators
nitric oxide production inhibitor
Source data
